期刊
BIOMEDICINES
卷 9, 期 3, 页码 -出版社
MDPI
DOI: 10.3390/biomedicines9030313
关键词
antiretroviral therapy (ART); antiretrovirals (ARVs); boosted protease inhibitor (PI); darunavir (DRV); ritonavir (RTV); cobicistat (COBI); HIV/AIDS
资金
- NIH [P41-GM103311]
Management of antiretroviral therapy in HIV+ patients faces challenges in improving patient adherence by selecting appropriate treatment regimens to reduce viremia, enhance immune response, and minimize adverse reactions. The use of protease inhibitor darunavir with enzyme inhibitors cobicistat or ritonavir has shown effectiveness in reducing HIV mortality and morbidity by impacting drug interactions and pharmacokinetics.
A major challenge in the management of antiretroviral therapy (ART) is to improve the patient's adherence, reducing the burden caused by the high number of drugs that compose the treatment regimens for human immunodeficiency virus positive (HIV+) patients. Selection of the most appropriate treatment regimen is responsible for therapeutic success and aims to reduce viremia, increase the immune system response capacity, and reduce the incidence rate and intensity of adverse reactions. In general, protease inhibitor (PI) is one of the pillars of regimens, and darunavir (DRV), in particular, is frequently recommended, along with low doses of enzyme inhibitors as cobicistat (COBI) or ritonavir (RTV), by the international guidelines. The potential of clinically significant drug interactions in patients taking COBI or RTV is high due to the potent inhibitory effect on cytochrome CYP 450, which attracts significant changes in the pharmacokinetics of PIs. Regardless of the patient or type of virus, the combined regimens of DRV/COBI or DRV/RTV are available to clinicians, proving their effectiveness, with a major impact on HIV mortality/morbidity. This study presents current information on the pharmacokinetics, pharmacology, drug interactions, and adverse reactions of DRV; it not only compares the bioavailability, pharmacokinetic parameters, immunological and virological responses, but also the efficacy, advantages, and therapeutic disadvantages of DRV/COBI or DRV/RTV combinations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据